Colorectal metastases to the liver: selective chemoembolization

Area of Science:

• Hepatobiliary Oncology
• Interventional Radiology
• Gastrointestinal Cancer Treatment

Background:

• Colorectal cancer frequently metastasizes to the liver, posing a significant challenge in treatment.
• Current treatment options for liver metastases include surgery, systemic chemotherapy, and locoregional therapies.
• Selective chemoembolization presents a targeted approach to deliver chemotherapy directly to liver tumors.

Purpose of the Study:

• To assess the efficacy and safety of selective chemoembolization for liver metastases originating from colorectal cancer.
• To determine the impact of this treatment on tumor response and patient survival.

Main Methods:

• A cohort of 46 patients with colorectal liver metastases underwent selective chemoembolization.
• The regimen involved doxorubicin and ethiodized oil, with 75% administered to subsegments and 25% to the main hepatic artery.
• Patient outcomes and survival were monitored.

Main Results:

• Complete disappearance of lesions and normalization of carcinoembryonic antigen levels were observed in 8 patients.
• Disease progression was halted for at least 12 months in 11 patients and 24 months in 2 patients.
• Survival rates varied, with 5-year follow-up in 6 patients and evidence of homogeneous agent distribution in long-term survivors.

Conclusions:

• Selective chemoembolization is a recommended treatment for colorectal liver metastases in patients with resectable primary tumors and no other metastatic disease.
• The procedure demonstrates potential for significant tumor control and improved outcomes.
• Further research may explore optimizing delivery and patient selection for this intervention.